RT Journal Article
SR Electronic
T1 Early immune responses have long-term associations with clinical, virologic, and immunologic outcomes in patients with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.27.21262687
DO 10.1101/2021.08.27.21262687
A1 Hu, Zicheng
A1 van der Ploeg, Kattria
A1 Chakraborty, Saborni
A1 Arunachalam, Prabhu
A1 Mori, Diego Martinez
A1 Jacobson, Karen B.
A1 Bonilla, Hector
A1 Parsonnet, Julie
A1 Andrews, Jason
A1 Hedlin, Haley
A1 de la Parte, Lauren
A1 Dantzler, Kathleen
A1 Ty, Maureen
A1 Tan, Gene S
A1 Blish, Catherine A.
A1 Takahashi, Saki
A1 Rodriguez-Barraquer, Isabel
A1 Greenhouse, Bryan
A1 Butte, Atul J.
A1 Singh, Upinder
A1 Pulendran, Bali
A1 Wang, Taia T.
A1 Jagannathan, Prasanna
YR 2021
UL http://medrxiv.org/content/early/2021/08/29/2021.08.27.21262687.abstract
AB The great majority of SARS-CoV-2 infections are mild and uncomplicated, but some individuals with initially mild COVID-19 progressively develop more severe symptoms. Furthermore, mild to moderate infections are an important contributor to ongoing transmission. There remains a critical need to identify host immune biomarkers predictive of clinical and virologic outcomes in SARS-CoV-2-infected patients. Leveraging longitudinal samples and data from a clinical trial of Peginterferon Lambda for treatment of SARS-CoV-2 infected outpatients, we used host proteomics and transcriptomics to characterize the trajectory of the immune response in COVID-19 patients within the first 2 weeks of symptom onset. We define early immune signatures, including plasma levels of RIG-I and the CCR2 ligands (MCP1, MCP2 and MCP3), associated with control of oropharyngeal viral load, the degree of symptom severity, and immune memory (including SARS-CoV-2-specific T cell responses and spike (S) protein-binding IgG levels). We found that individuals receiving BNT162b2 (Pfizer–BioNTech) vaccine had similar early immune trajectories to those observed in this natural infection cohort, including the induction of both inflammatory cytokines (e.g. MCP1) and negative immune regulators (e.g. TWEAK). Finally, we demonstrate that machine learning models using 8-10 plasma protein markers measured early within the course of infection are able to accurately predict symptom severity, T cell memory, and the antibody response post-infection.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04331899Funding StatementSupport for the study was provided from NIH/NIAID (U01 AI150741-01S1 to ZH, ST, IRB, BG, TW, and PJ), Stanford Innovative Medicines Accelerator, and NIH/NIDA DP1DA046089. The Lambda clinical trial was funded by anonymous donors to Stanford University, and Peginterferon Lambda provided by Eiger BioPharmaceuticals. The funders had no role in data collection and analysis or the decision to publish. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of Stanford University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe will be available upon request.